Anti-Human TNF receptor (p 75) IgG | Gentaur

(No reviews yet) Write a Review
SKU:
30-MR-091-7(75)-GEN
Availability:
IN STOCK
€340.00
Frequently bought together:

Description

Anti-Human TNF receptor (p 75) IgG

Species Reactivity Human
 
Specificity Detects human TNF RI in Western blots. In Western blots, does not cross-react with recombinant human (rh)
TNF RII, rmTNF RI, or rmTNF RII.
 
Source Monoclonal Mouse IgG1 Clone # 16803
 
Purification Protein A or G purified from hybridoma culture supernatant
 
Immunogen E. coli-derived recombinant human TNF RI/TNFRSF1A
Accession # NP_001056
 
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
 
Endotoxin Level <0.10 EU per 1 μg of the antibody by the LAL method.
 
Label Unconjugated

Tumor necrosis factor (TNF) is a central regulator of immunity. Due to its dominant pro-inflammatory effects, drugs that neutralize TNF were developed and are clinically used to treat inflammatory and autoimmune diseases, such as rheumatoid arthritis, inflammatory bowel disease and psoriasis. However, despite their clinical success the use of anti-TNF drugs is limited, in part due to unwanted, severe side effects and in some diseases its use even is contraindicative.

With gaining knowledge about the signaling mechanisms of TNF and the differential role of the two TNF receptors (TNFR), alternative therapeutic concepts based on receptor selective intervention have led to the development of novel protein therapeutics targeting TNFR1 with antagonists and TNFR2 with agonists.

These antibodies and bio-engineered ligands are currently in preclinical and early clinical stages of development. Preclinical data obtained in different disease models show that selective targeting of TNFRs has therapeutic potential and may be superior to global TNF blockade in several disease indications.

Tumor necrosis factor (TNF) is a key regulatory component of the immune system that regulates innate and adaptive immunity and contributes to initiation and maintenance of inflammation (Aggarwal, 2003). The major cellular source of TNF are macrophages and immune cells that are activated in response to infections or tissue damage (Fischer and Maier, 2015). Therefore, regulated TNF expression is essential to promote tissue homeostasis and fight infections.

In contrast, deregulated TNF expression and signaling may induce pathology resulting in chronic inflammation and tissue damage. Indeed, increased levels of TNF were identified in patients with autoimmune and degenerative diseases (Fischer and Maier, 2015; Monaco et al., 2015). To counteract the pro-inflammatory and tissue degenerative effects of TNF signaling, therapeutics have been developed that neutralize TNF.

Currently, five structurally different anti-TNF drugs are approved for clinical use: infliximab (Remicade), adalimumab (Humira), certolizumab pegol (Cimzia), golimumab (Simponi), and etanercept (Enbrel) (Monaco et al., 2015). These anti-TNF therapeutics, and biosimilars of infliximab, etanercept and adalimumab that have been approved recently, are successfully used to treat autoimmune diseases, including RA, juvenile RA (JRA), IBD, psoriasis, and ankylosing spondylitis (AS) (Monaco et al., 2015).

Despite the clinical success of anti-TNF therapeutics they also show limitations, such as their restricted responsiveness, and severe side-effects, such as opportunistic infections, invasive fungal infections, reactivation of tuberculosis, and development of other autoimmune diseases and lymphomas (Tracey et al., 2008; Monaco et al., 2015).

Further, clinical evaluation of anti-TNF therapy in multiple sclerosis failed (van Oosten et al., 1996; Lenercept Study Group, 1999) and anti-TNF therapy of juvenile rheumatoid arthritis resulted in development of MS-like exacerbations and demyelinating lesions in some patients (Sicotte and Voskuhl, 2001). Altogether this indicates that the use of anti-TNF drugs is limited and contraindicative for several indications, including neurodegenerative diseases.

The limitations of anti-TNF therapy may depend on TNF’s pleiotropic biological functions via two distinct TNF receptors (TNFR). Synthesized as a transmembrane protein (tmTNF), the tmTNF form can activate both, TNFR1 and TNFR2. After proteolytical processing, the soluble trimers (sTNF) mainly activate TNFR1 (Fischer et al., 2015).

In different animal disease models, genetic deletion of TNFR1 is typically associated with lack or reduced disease, whereas TNFR2 ablation exacerbates disease. These and other data indicate that sTNF/TNFR1 signaling mainly mediates pro-apoptotic and inflammatory responses, whereas TNFR2 contributes to immune regulation and tissue regeneration. Therefore, reagents that selectively target TNFRs might be superior to global TNF blockade because they allow a differential activation and/or inhibition of TNFRs.

View AllClose

Additional Information

Size:
100 µg
View AllClose